Gilead Sciences, Inc.
GILD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.62 | 0.74 | -0.90 | 0.00 |
| FCF Yield | 8.95% | 7.34% | 7.74% | 11.85% |
| EV / EBITDA | 29.75 | 11.43 | 14.41 | 9.94 |
| Quality | ||||
| ROIC | 2.36% | 11.82% | 10.62% | 12.84% |
| Gross Margin | 78.26% | 76.04% | 79.26% | 75.82% |
| Cash Conversion Ratio | 22.56 | 1.41 | 1.98 | 1.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.77% | -0.23% | 3.38% | 6.75% |
| Free Cash Flow Growth | 38.86% | -11.06% | -22.78% | 43.72% |
| Safety | ||||
| Net Debt / EBITDA | 3.77 | 1.80 | 2.24 | 1.89 |
| Interest Coverage | 1.70 | 8.06 | 7.84 | 9.91 |
| Efficiency | ||||
| Inventory Turnover | 3.66 | 3.64 | 3.75 | 4.08 |
| Cash Conversion Cycle | 107.32 | 132.21 | 102.75 | 110.54 |